ESMO 2020 Abstract Analysis - BioTrack

1. Precision Medicine is evolving
at a rapid pace
BioTrack
ESMO 2020 Abstract Analysis
For inquiries and further details, get in touch with our team at
madan@decibio.com | www.decibio-analytics.com
How are you keeping up?
Precision Medicine BioTrack
PrecisionMedicine.Live
Create your free account at
SEPT 2020

2. Precision Medicine BioTrack
1,812ABSTRACTS ANALYZED ON BIOTRACK
BioTrack simplifies your workflow in 3 simple steps
Aggregates data from multiple sources
Automatically annotates & ranks relevant content based on your preferences
Enables sharing of data-driven insights with your team
1.
2.
3.
Click here to view the ESMO feed

3. Patterns of acquired mutations in estrogen receptor-positive metastatic breast cancer (MBC)
patients identified by comprehensive genomic profiling (CGP)
RB1, ESR1, CGP (TISSUE & BLOOD (FOUNDATIONONE CDX / LIQ.), ER, PD-L1 (SP142), TP53, FGFR1,
FGF3/ FGF4/ FGF19, PIK3CA, ERBB2, MSI, TMB
An exploration of ARID1A mutations in circulating cell-free DNA (cfDNA) from 68,000
advanced cancer patients: Implications for tumor biology and therapeutic response
ARID1A, CGP (GUARDANT360), PIK3CA, KRAS, ERBB2, BRCA1, BRCA2, MSI-H, BRAF-V600E, NRAS
Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial
carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-
label, single-arm, phase II ARCADIA trial
PD-L1 (SP142), TMB (FOUNDATIONONE)
PD-L1, tumor mutational burden, and overall survival among patients undergoing
surgical treatment for hepatocellular carcinoma prior to systemic therapy
PD-L1 (SP142), TMB (FOUNDATIONONE)
Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next
generation sequencing panel and clinical outcome in non-small cell lung cancer
TMB (TSO500), HLA-DIVERSITY
Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients
for treatment with entrectinib
NTRK, ROS1, CGP (FOUNDATIONONE LIQUID CDX)
Select Precision Medicine Abstracts of Interest
Precision Medicine BioTrack
Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers
MDM2, CGP (CARIS), TP53, KRAS, APC, PIK3CA, ATM, CDK4, ERBB3, HMGA2, LGR5, NACA, WIF1,
TMB, MSI, DMMR, PD-L1, GNAS
Spatial-statistics-based modeling for predicting treatment response in non-small cell lung
cancer (NSCLC) patients using H&E pathology images
DIGITAL / COMPUTATIONAL PATHOLOGY
Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts)
from blood first assay screening trial (BFAST) and comparison with real-world data (RWD)
CGP (FOUNDATIONACT), REAL-WORLD DATA (RWD; FLATIRON-FMI CGDB), EGFR, KRAS, ALK,
ROS1, RET, BRAF-V600, METEX14, PIK3CA
Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in
patients treated with immune checkpoint blockers for metastasized melanoma
SPD1,SPDL1, SLAG3, STIM3, CD3+CD8+PD1+T-CELLS, CD3+CD8+KI67+ T-CELLS,EOSINOPHILS,
TIM3+ T-CELLS, LAG3+ T-CELLS
VIEW ALL ABSTRACTS
ABSTRACT TITLE AND RELEVANT TAGS | CLICK TO VIEW ABSTRACTKEY COMPANIES

4. Key Companies Mentioned
Precision Medicine BioTrack
0 25 50 75
Roche
Merck
AstraZeneca
BMS
Pfizer
Novartis
Bayer
Agilent
Serono
Roche Diagnostics
Eli Lilly
Flatiron Health
Janssen
Illumina
NanoString
GSK
Seattle Genetics
Amgen
Astellas
Genentech
Takeda
Sanofi
Celgene
Syneos Health
Daiichi Sankyo
Thermo Fisher
Caris
Guardant Health
Qiagen
Quintiles
Biocartis
Natera
Regeneron
Singlera Genomics
Note: Counts calculated automatically based on pre-selected list of tags and have not been manually reviewed. may vary from actual counts and segmentations

5. Key Biomarkers Mentioned
Precision Medicine BioTrack
0 50 100 150 200 250
PD-L1
PD1
EGFR
HER2
BRAF
TMB
BRCA1
KRAS
ALK
BRCA2
MSI
CD8
ctDNA
PIK3CA
RAS
MET
VEGF
Fusion
CDK4/6
TIL
RET
mRNA
MMR
CD3
MEK
cfDNA
NTRK
NRAS
Gene Signature
HRD
PTEN
Note: Counts calculated automatically based on pre-selected list of tags and have not been manually reviewed. may vary from actual counts and segmentations

6. Key Technologies Mentioned
Precision Medicine BioTrack
0 50 100 150 200
Next-generation sequencing
IHC
PCR
RNA-Seq
qPCR
Flow cytometry
AI / ML
rt-PCR
ELISA
FISH
Hybridization
Microarray
Mass Spectometry
DNA-Seq
nCounter
dPCR
mIHC
CRISPR
mIF
RNAscope
Compuational image analysis
CISH
0 20 40 60
GEP
CDx
CGP
Liquid Biopsy
Screening
Prognostic
Single Cell
Disease Relapse
Recurrence Monitoring
Multiomics
Digital pathology
Clinical Decision Support
Functional Assays
Dx / Assay
Key Applications Mentioned
Note: Counts calculated automatically based on pre-selected list of tags and have not been manually reviewed. may vary from actual counts and segmentations

7. Key TA's Mentioned
Precision Medicine BioTrack
0 100 200 300 400
Lung Cancer
Breast Cancer
Adjuvant
Colorectal Cancer
Metastatic Cancer
Coronavirus
Melanoma
Advanced Solid Tumor
Ovarian Cancer
Prostate Cancer
Head and Neck cancer
Gastric Cancer
mCRPC
Kidney Cancer
Bladder Cancer
Liver Cancer
Triple-negative breast cancer
Pancreatic Cancer
Lymphoma
Cervical Cancer
Brain Cancer
Leukemia
Glioblastoma multiforme
Cancer of Unknown Primary
Multiple Myeloma
Esophageal cancer
Myelodysplastic syndrome
Diffuse large b-cell lymphoma
Nasopharyngeal cancer
Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Myelofibrosis
Note: Counts calculated automatically based on pre-selected list of tags and have not been manually reviewed. may vary from actual counts and segmentations

8. View the live feed at
PrecisionMedicine.Live